An international, peer-reviewed journal publishing monographs on new products entering the market and review articles.Since its inception in 1965, Drugs of Today has established a reputation for excellence in providing physicians and other key healthcare professionals with practical, up-to-date monographs on recently approved and launched drugs.
国际同行评审期刊，发表有关新产品进入市场的专著和评论文章。自1965年创刊以来，《今日药物》在为医生和其他关键医疗保健专业人士提供有关最近批准和上市药物的实用、最新专著方面建立了卓越的声誉。
10th World Orphan Drug Congress (WODC) (November 12-14, 2019 - Barcelona, Spain).
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.12.3107705
A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.6.2969816
Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.1.2914339
Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.2.2903217
American Society of Clinical Oncology (ASCO) - 55th Annual Meeting (May 31-June 4, 2019 - Chicago, Illinois, USA).
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.6.3024181
Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.3.2909248
Viltolarsen for the treatment of Duchenne muscular dystrophy.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.10.3045038
Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.4.2958476
Erdafitinib to treat urothelial carcinoma.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.8.3010573
Patisiran for the treatment of patients with familial amyloid polyneuropathy.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.5.2958475
Fremanezumab for the prevention of chronic and episodic migraine.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.4.2970909
Fexinidazole for the treatment of human African trypanosomiasis.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.11.3068795
Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.4.2930713
Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.4.2965337
Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.6.2999889
Brexanolone for the treatment of patients with postpartum depression.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.9.3040864
Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.6.2984806
Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.9.3039670
Talazoparib to treat BRCA-positive breast cancer.
来源期刊：Drugs of TodayDOI：10.1358/DOT.2019.55.7.3015642
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.8.3005176
Lanadelumab to treat hereditary angioedema.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.7.2985293
Lenvatinib mesylate to treat hepatocellular carcinoma.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.5.2969817
Lorlatinib for the treatment of patients with non-small cell lung cancer.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.2.2927983
Eptinezumab for the treatment of migraine.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.11.3069864
Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.9.3039669
Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.6.2989843
Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.1.2895651
The neurobiology under the placebo effect.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.7.3010575
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (November 4-6, 2019 - Copenhagen, Denmark).
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.11.3100502
Condoliase for treatment of lumbar disc herniation.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.1.2899445
Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.3.2903216
Contraceptive vaginal ring containing segesterone acetate and ethinyl estradiol: long-acting, patient-controlled, procedure-free, reversible prescription birth control.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.7.2965363
Combating colorectal cancer with immunotherapy: Where are we?
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.8.2999891
The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.9.3020159
Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.7.2958474
Unintended consequences of the new ACC/AHA blood pressure treatment guidelines.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.4.2954407
Targeted therapies for ROS1-rearranged non-small cell lung cancer.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.10.3030646
BIO-Europe Spring 2019 - 13th Annual International Partnering Conference (March 25-27, 2019 - Vienna, Austria).
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.5.2996481
Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.12.3058917
Triclabendazole for the treatment of fascioliasis.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.12.3058861
Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.10.3030645
Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.5.2962947
The 2019 TOPRA (Organization for Professionals in Regulatory Affairs) Annual Symposium (September 30-October 2, 2019 - Dublin, Ireland).
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.10.3084505
World Pharma Pricing and Market Access Congress - 11th Terrapinn Congress (March 19-20, 2019 - Amsterdam, the Netherlands).
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.4.2996479
Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.12.3078389
LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.5.2976501
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.11.3035584
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
来源期刊：Drugs of todayDOI：10.1358/dot.2019.55.11.3068796
